Lattice Biologics (TSXV:LBL.H) EV-to-Revenue : 2.52 (As of Jun. 11, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lattice Biologics's enterprise value is C$5.10 Mil. Lattice Biologics's Revenue for the trailing twelve months (TTM) ended in Jun. 2021 was C$2.02 Mil. Therefore, Lattice Biologics's EV-to-Revenue for today is 2.52.

The historical rank and industry rank for Lattice Biologics's EV-to-Revenue or its related term are showing as below:

TSXV:LBL.H's EV-to-Revenue is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 3.1
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-11), Lattice Biologics's stock price is C$0.04. Lattice Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was C$0.02. Therefore, Lattice Biologics's PS Ratio for today is 2.35.

Lattice Biologics EV-to-Revenue Historical Data

The historical data trend for Lattice Biologics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics EV-to-Revenue Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

EV-to-Revenue

Get a 7-Day Free Trial

3.92

3.65

4.23

1.93

2.82

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
EV-to-Revenue	Get a 7-Day Free Trial															3.25	2.82	3.32	2.59	2.53

Competitive Comparison of Lattice Biologics's EV-to-Revenue

For the Medical Devices subindustry, Lattice Biologics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lattice Biologics's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's EV-to-Revenue falls into.

Lattice Biologics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Lattice Biologics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	5.096	/	2.023
	=	2.52

Lattice Biologics's current Enterprise Value is C$5.10 Mil.
Lattice Biologics's Revenue for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.02 Mil.

Lattice Biologics (TSXV:LBL.H) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Lattice Biologics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.04	/	0.017
	=	2.35

Lattice Biologics's share price for today is C$0.04.
Lattice Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.02.

Lattice Biologics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lattice Biologics (TSXV:LBL.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines